How Cyclica is addressing two key biotech challenges
In this video, Naheed Kurji (Cyclica’s CEO, President, & Co-Founder) discusses how we’re addressing two key biotech challenges: 1) Most early stage biotech companies focus on one or a select few lead drug discovery programs, and a single program has only a 4% chance of approval, 2) Current drug discovery programs only target 7% of possible protein targets.
Learn more about our mission to address these challenges with our team, platform, and business model in our corporate manifesto here: https://cyclicarx.com/press-releases/....